<code id='D82624440C'></code><style id='D82624440C'></style>
    • <acronym id='D82624440C'></acronym>
      <center id='D82624440C'><center id='D82624440C'><tfoot id='D82624440C'></tfoot></center><abbr id='D82624440C'><dir id='D82624440C'><tfoot id='D82624440C'></tfoot><noframes id='D82624440C'>

    • <optgroup id='D82624440C'><strike id='D82624440C'><sup id='D82624440C'></sup></strike><code id='D82624440C'></code></optgroup>
        1. <b id='D82624440C'><label id='D82624440C'><select id='D82624440C'><dt id='D82624440C'><span id='D82624440C'></span></dt></select></label></b><u id='D82624440C'></u>
          <i id='D82624440C'><strike id='D82624440C'><tt id='D82624440C'><pre id='D82624440C'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:737
          Amylyx founders
          Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

          The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

          Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

          advertisement

          The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          Illumina to lay off 10% of research and development team
          Illumina to lay off 10% of research and development team

          AdobeSANDIEGO—Monthsafterannouncingplanstocutcostsby$100million,DNAsequencinggiantIlluminahasbegunto

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          GOP inquiry over gain

          BernardMossCourtesyNIAIDFormorethanhalfacentury,scientistBernardMosshasbeencommandingtheattentionofp